These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37794556)

  • 1. Hyperpigmentation on head and neck caused by polymyxin B: A rare case.
    Kaya F; Tuğcugil E
    Niger J Clin Pract; 2023 Sep; 26(9):1393-1395. PubMed ID: 37794556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process.
    Mattos KPH; Cintra ML; Gouvêa IR; Ferreira LÁ; Velho PENF; Moriel P
    J Clin Pharm Ther; 2017 Oct; 42(5):573-578. PubMed ID: 28497462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.
    Zheng G; Cao L; Che Z; Mao E; Chen E; He J
    BMC Pharmacol Toxicol; 2018 Jul; 19(1):41. PubMed ID: 29973293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head and Neck Hyperpigmentation Probably Associated with Polymyxin B Therapy.
    Zavascki AP; Manfro RC; Maciel RA; Falci DR
    Ann Pharmacother; 2015 Oct; 49(10):1171-2. PubMed ID: 26187742
    [No Abstract]   [Full Text] [Related]  

  • 5. Polymyxin B-induced skin hyperpigmentation.
    Li YM; Milikowski C; Selvaggi G; Abbo LM; Skiada D; Galimberti F
    Transpl Infect Dis; 2020 Oct; 22(5):e13312. PubMed ID: 32386075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyxin B-induced rhabdomyolysis: A case report.
    Ni M; Meng X; Wang L; Zhao Y; Yu M; Shi S
    Medicine (Baltimore); 2020 Oct; 99(43):e22924. PubMed ID: 33120846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyxin B-related neurotoxicity: a brief case report.
    Bayraktar I; Halacli B; Demirkan K; Topeli A
    Eur J Hosp Pharm; 2023 Dec; 31(1):66-67. PubMed ID: 37286311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment.
    Mattos KPH; Gouvêa IR; Quintanilha JCF; Cursino MA; Vasconcelos PENS; Moriel P
    J Clin Pharm Ther; 2019 Jun; 44(3):415-419. PubMed ID: 30666679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical analysis of sepsis with extensively drug resistant Gram-negative bacteria in intensive care unit treated with polymyxin B-based combination therapy].
    Zhao S; Yan L; Wang C; Peng M
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Feb; 32(2):150-154. PubMed ID: 32274997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR
    Pan S; Huang X; Wang Y; Li L; Zhao C; Yao Z; Cui W; Zhang G
    Antimicrob Resist Infect Control; 2018; 7():8. PubMed ID: 29387342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective observational study of the treatment with polymyxin B for liver transplantation recipients infected by multidrug-resistant gram-negative bacteria.
    Yu LL; Shi XP; Huang JF; Gong Y; Cui CX; Wang T
    J Clin Pharm Ther; 2022 Oct; 47(10):1563-1569. PubMed ID: 35670240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.
    Zavascki AP; Schuster LF; Duquia RP
    Int J Antimicrob Agents; 2016 Nov; 48(5):579-580. PubMed ID: 27720305
    [No Abstract]   [Full Text] [Related]  

  • 13. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria.
    Ouderkirk JP; Nord JA; Turett GS; Kislak JW
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2659-62. PubMed ID: 12878536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study on intravenous combined with aerosol inhalation of polymyxin B for the treatment of pneumonia caused by multidrug-resistant Gram-negative bacteria].
    Zhou L; Li C; Weng Q; Wu J; Luo H; Xue Z; Xiao Y; Chen C
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Apr; 33(4):416-420. PubMed ID: 34053483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B.
    Zhou Y; Li Y; Xie X; Song L; Lan G; Sun B; Tang T; Yan H; Zhang B; Xu P
    Br J Clin Pharmacol; 2022 Nov; 88(11):4742-4750. PubMed ID: 35508710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic Response Revealed Signaling Pathways Involving in the Mechanism of Polymyxin B-Induced Melanogenesis.
    Zhang C; Liu X; Wu H; Wang Y; Fan Y; Guo B; Bian X; Li X; Zhang J
    Microbiol Spectr; 2022 Apr; 10(2):e0273021. PubMed ID: 35377227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
    Liang R; Wang D; Hu M; Gu Y; Wang M; Hu D; Zhu M; Wang M
    J Antibiot (Tokyo); 2023 Sep; 76(9):540-547. PubMed ID: 37217796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam.
    Fitzpatrick MA; Esterly JS; Postelnick MJ; Sutton SH
    Ann Pharmacother; 2012; 46(7-8):e17. PubMed ID: 22811349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.
    Holloway KP; Rouphael NG; Wells JB; King MD; Blumberg HM
    Ann Pharmacother; 2006 Nov; 40(11):1939-45. PubMed ID: 17018688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant Acinetobacter baumannii.
    Thomas VM; Brown RM; Ashcraft DS; Pankey GA
    Int J Antimicrob Agents; 2019 May; 53(5):663-668. PubMed ID: 30880230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.